Investec began coverage on shares of Alliance Pharma plc (LON:APH) in a report issued on Wednesday morning. The firm issued a buy rating and a GBX 59 ($0.76) price objective on the stock.

APH has been the topic of a number of other research reports. FinnCap decreased their price objective on Alliance Pharma plc from GBX 65 ($0.84) to GBX 58 ($0.75) and set a buy rating on the stock in a research note on Monday, July 31st. Numis Securities Ltd reaffirmed a buy rating and set a GBX 60 ($0.77) price objective on shares of Alliance Pharma plc in a research note on Thursday, May 25th.

Alliance Pharma plc (APH) opened at 52.75 on Wednesday. The stock’s 50 day moving average price is GBX 52.51 and its 200 day moving average price is GBX 50.61. The stock’s market cap is GBX 249.36 million. Alliance Pharma plc has a 12-month low of GBX 41.33 and a 12-month high of GBX 57.56.

ILLEGAL ACTIVITY NOTICE: “Alliance Pharma plc (APH) Earns Buy Rating from Analysts at Investec” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/17/alliance-pharma-plc-aph-earns-buy-rating-from-analysts-at-investec.html.

About Alliance Pharma plc

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.

Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with MarketBeat.com's FREE daily email newsletter.